Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

RSVTriVax

Financiado

Cerrado

Development of a trivalent epitope focused RSV vaccine to boost pre existing imm...

Development of a trivalent epitope focused RSV vaccine to boost pre existing immunity The development of a Respiratory Syncytial Virus (RSV) vaccine is deemed a global health priority by the World Health Organization. Globally, RSV causes 33 million episodes of infection and up to 120,000 deaths annually. The most... ver más

30/09/2021

EPFL

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-09-30

ERC-2019-POC: ERC Proof of Concept Grant Scope:Eligible Countries

I+D

Cerrada

0% 100% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

EPFL

150.00K€ | Lider

ECO OCI

165.65K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 25 meses Fecha Inicio: 2019-08-21
Fecha Fin: 2021-09-30

Líder del proyecto

ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 150K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The development of a Respiratory Syncytial Virus (RSV) vaccine is deemed a global health priority by the World Health Organization. Globally, RSV causes 33 million episodes of infection and up to 120,000 deaths annually. The most affected populations are pre-term infants, young children and the elderly. Several decades of intensive research are yet to yield a clinically approved vaccine. This failure is mostly attributed to sophisticated viral mechanisms that prevent the induction of protective antibodies (Abs). Using cutting-edge molecular design tools, we developed a novel vaccine candidate (TriVax) to focus immune responses in such key neutralization epitopes. TriVax is a cocktail composed of three epitope-focused immunogens mimicking three distinct neutralization epitopes targeted by potent neutralizing Abs. Our primary target populations are pregnant women (protection of pre-term infants) and elderly, where the challenge is to boost subdominant, neutralizing Abs elicited during previous natural infections. Recently, we showed that epitope-focused immunogens are exquisite at boosting subdominant functional Abs, and in this scenario, superior to the strongest competitor vaccine candidates. In a preliminary study in Non-Human Primates, TriVax showed great promise by eliciting robust neutralization on an RSV naïve cohort, suggesting a good safety profile and the potential to emerge as a competitive alternative for vaccine development. For manufacturing, epitope-focused immunogens are simple and stable molecules that can be produced at low cost. Overall, we propose a viable vaccine formulation to protect against an important pathogen which carries large financial burdens on public health systems. Thus, our proposal has an important societal and financial impact, and will provide compelling evidence for Trivax to boost neutralizing Abs in a close-to-human animal model, thereby taking an essential step to consolidate the commercial potential of our vaccine.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores